about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasImmunotherapy for Gastroesophageal CancerHematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Chimeric antigen receptor T-cell therapies for lymphoma.Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Promising Novel Agents for Aggressive B-Cell Lymphoma.The landscape of new drugs in lymphomaQuantitative Imaging Approaches to Study the CAR Immunological Synapse.Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityTumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Current Progress in EBV-Associated B-Cell Lymphomas.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Chimeric antigen receptor transduced T cells: Tuning up for the next generation.Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.New Chimeric Antigen Receptor Design for Solid Tumors.Redox control of cancer cell destruction.Targeting Immune System Alterations in Hodgkin Lymphoma.Versatile CAR T-cells for cancer immunotherapy.The application of CAR-T cell therapy in hematological malignancies: advantages and challengesCRISPR-mediated genome editing and human diseases
P2860
Q26749139-B7B435B5-F624-40F6-A5F5-98A3A3182FE9Q28069873-4D7C5B4D-48B8-49B9-9E26-814A7C7FEDEAQ28072887-2FBE70D9-556A-4B28-82FD-D1BFF12CE9DBQ36951719-BEC1F8C7-58CE-478E-8C67-27D1DBBF2311Q37609801-7C353811-2B44-40F6-8175-4858F4E9E925Q38600697-8D0E875B-6EE3-403B-B7E8-C853603FDB44Q38714964-C67D33AA-4651-4173-9AD7-1F3D12CAE987Q38847756-CA2AA669-D606-4D06-95CB-B1889F3232F1Q38913549-D2C75E16-34E7-4C2B-BB18-219D9E361BA5Q39020641-86D72B3A-E731-453F-948D-8EF8F4AC1D74Q39061630-4F2C4C56-C926-4580-9FCA-AB82C683EB4AQ39405625-F7DCF48D-8D38-489C-AB17-24A20D5529A8Q40015002-F45B438B-131B-4AEA-B782-A66A669B7159Q40095482-7B979271-30E9-4F39-88E6-83A45698B7EBQ42657377-E79C799F-160E-4E2A-9111-0067E067B744Q47218634-787C7E0C-2C56-43F1-8490-A53C2CC86E35Q47606345-0C93E89B-46A3-4EA5-829E-5117F7F04A04Q48255324-85E67580-D376-425C-87AD-B38412DE4364Q48337005-B4BF0048-B3C1-48DA-9E22-5784A7F19363Q49363296-BC614754-9FF3-4377-94BD-1A9D1EE9E38BQ49711158-E043932D-77B9-4F64-937F-18E70B9AA67AQ51748168-C8697D9C-95F6-4C0A-845A-E13C2466D3A1Q53123844-043E42D8-C830-4086-A906-98F0935C1E09Q55347731-41CF93A4-F4D6-4BDE-9287-D7A53A77B96EQ57177485-AD02EFC2-06DE-43C2-8DB8-54298067FADEQ57253681-B8836DA5-8B04-44FD-92E2-BF9AA19234B5
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CAR-T Cell Therapy for Lymphoma.
@ast
CAR-T Cell Therapy for Lymphoma.
@en
type
label
CAR-T Cell Therapy for Lymphoma.
@ast
CAR-T Cell Therapy for Lymphoma.
@en
prefLabel
CAR-T Cell Therapy for Lymphoma.
@ast
CAR-T Cell Therapy for Lymphoma.
@en
P2860
P1476
CAR-T Cell Therapy for Lymphoma
@en
P2093
Helen E Heslop
Malcolm K Brenner
P2860
P304
P356
10.1146/ANNUREV-MED-051914-021702
P577
2015-08-26T00:00:00Z